Current Oncology | Free Full-Text | Precision Oncology in Gastrointestinal Stromal Tumors
A new monoclonal antibody that blocks dimerisation and inhibits c-kit mutation-driven tumour growth | Journal of Cancer Research and Clinical Oncology
Computational Analysis of the Binding Specificity of Gleevec to Abl, c-Kit, Lck, and c-Src Tyrosine Kinases | Journal of the American Chemical Society
Diapositiva 1
Reactome | Drug resistance of KIT mutants
Cancer drug gets a makeover | News | Chemistry World
Loss of PI3 kinase association improves the sensitivity of secondary mutation of KIT to Imatinib | Cell & Bioscience | Full Text
Imatinib Mesylate — A New Oral Targeted Therapy | NEJM
Presentazione standard di PowerPoint
Frontiers | An overview of agents and treatments for PDGFRA-mutated gastrointestinal stromal tumors
Secondary KIT mutations: the GIST of drug resistance and sensitivity | British Journal of Cancer
Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours | British Journal of Cancer
Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations - The Lancet Oncology
Frontiers | Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor
The KIT receptor tyrosine kinase. (A) C-KIT mutations occur in 80 –90%... | Download Scientific Diagram
Ripretinib in advanced gastrointestinal stromal tumors: an overview of current evidence and drug approval | Future Oncology
A novel anti‐c‐Kit antibody–drug conjugate to treat wild‐type and activating‐mutant c‐Kit‐positive tumors - Kim - 2022 - Molecular Oncology - Wiley Online Library
![PDF] The SCF/c-KIT system and imatinib actions in prostate cancer: a cross-talk with RGN? | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/52568705464442ace5fec86bca4a1528e3281c4b/70-FigureV-1.png "PDF] The SCF/c-KIT system and imatinib actions in prostate cancer: a cross-talk with RGN? | Semantic Scholar")
PDF] The SCF/c-KIT system and imatinib actions in prostate cancer: a cross-talk with RGN? | Semantic Scholar
Mechanisms of Disease Persistence in Gastrointestinal Stromal Tumors - The Life Raft Group
Mechanism of action of imatinib. A) Under physiological conditions, ATP... | Download Scientific Diagram
Clinicopathological significance of c-KIT mutation in gastrointestinal stromal tumors: a systematic review and meta-analysis | Scientific Reports
Frontiers | Systemic Mastocytosis: Following the Tyrosine Kinase Inhibition Roadmap
GIST Mutations - Types of GIST Cancer Gene Mutations & Testing | The Life Raft Group
KIT mutation | The Hong Kong College of Pathologists
IJMS | Free Full-Text | Mutated KIT Tyrosine Kinase as a Novel Molecular Target in Acute Myeloid Leukemia
JCI - Structural reengineering of imatinib to decrease cardiac risk in cancer therapy
